Fonar Corporation (FONR)vsWaters Corporation (WAT)
FONR
Fonar Corporation
$19.09
0.00%
HEALTHCARE · Cap: $120.20M
WAT
Waters Corporation
$480.07
+0.67%
HEALTHCARE · Cap: $47.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 4309% more annual revenue ($4.64B vs $105.34M). FONR leads profitability with a 6.3% profit margin vs 3.6%. FONR trades at a lower P/E of 19.1x. WAT earns a higher WallStSmart Score of 43/100 (D).
FONR
Hold38
out of 100
Grade: F
WAT
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.7%
Fair Value
$14.66
Current Price
$19.09
$4.43 premium
Margin of Safety
-44.6%
Fair Value
$227.71
Current Price
$480.07
$252.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Smaller company, higher risk/reward
ROE of 5.5% — below average capital efficiency
6.3% margin — thin
Weak financial health signals
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FONR
The strongest argument for FONR centers on Price/Book, Altman Z-Score, Debt/Equity.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : FONR
The primary concerns for FONR are Market Cap, Return on Equity, Profit Margin.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 121.5x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
FONR profiles as a value stock while WAT is a hypergrowth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.15 — expect wider price swings.
WAT is growing revenue faster at 113.4% — sustainability is the question.
WAT generates stronger free cash flow (153M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (43/100 vs 38/100) and 113.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?